Evaluations of pathogenesis of cardiovascular disease and cardiovascular event risk in patients undergoing hemodialysis by biomarkers for cardiovascular disease

Evaluations of pathogenesis of cardiovascular disease and cardiovascular event risk in patients undergoing hemodialysis by biomarkers for cardiovascular disease - Biomarkers for cardiovascular disease in hemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036598

Enrollment

250

Registered

2019-05-01

Start date

2019-05-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients undergoing hemodialysis at Oyokyo Kidney Research Institute Hirosaki Hospital 2. Minimal dialysis vintage 3 month 3. Age more than 20 years old and older 4. Patients who can understand the purpose and content of this study and give written informed consent

Exclusion criteria

Exclusion criteria: 1.Patients with active infectious disease 2.History of autoimmune disease 3.History of malignancy 4.Kidney transplantation planned

Design outcomes

Primary

Measure	Time frame
Association of biomarkers for cardiovascular disease such as Pentraxin 3 and soluble lectin-like oxidized LDL receptor-1 with cardiovascular events in hemodialysis patients for 2 years follow-up period	—

Secondary

Measure	Time frame
Clinical and laboratory factors associated with Pentraxin 3 and soluble lectin-like oxidized LDL receptor-1 levels in hemodialysis patients including all cause mortality	—

Countries

Japan

Contacts

Public ContactHiroshi Osawa

Hirosaki University Hospital Department of General Medicie

osawa@hirosaki-u.ac.jp0172395177

Outcome results